Actively Recruiting
Title of Manuscript: Development and Internal-external Validation of a Comprehensive Model for Predicting Risk of Post-RFA Recurrence in HCC Patients
Led by Tian'an Jiang · Updated on 2024-08-29
6000
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Background A predictive model for post radiofrequency ablation (RFA) recurrence in patients with Hepatocellular carcinoma (HCC) that incorporates variables like sleep quality and psychological factors can provide more time to prevent the recurrence. Our aim is to investigate the relationship between these factors and post-RFA recurrence, and to construct a predictive model includes these highly preventable factors. Methods We collected data from HCC patients who underwent RFA for the first time from January 1, 2015, to July 2023, assessing their sleep quality, anxiety, and depression levels. We employed Restricted cubic splines (RCS), mediation analysis, Cox proportional hazards model, Elastic network Cox proportional hazards, Competitive risk model to ascertain the relationship between these factors and post-RFA recurrence. We then constructed a predictive model incorporating these factors, and evaluated the model's performance through internal and external validation datasets partitioning by time period.
CONDITIONS
Official Title
Title of Manuscript: Development and Internal-external Validation of a Comprehensive Model for Predicting Risk of Post-RFA Recurrence in HCC Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed as primary HCC according to the diagnostic criteria for primary liver cancer in China
- Either a solitary tumor with a diameter less than 5 cm or 2-3 tumors each with a maximum diameter less than 3 cm
- Radiofrequency ablation (RFA) as the initial treatment
- Agreed to participate in the study and submitted the completed questionnaire survey
- A follow-up period exceeding 6 months after ablation
You will not qualify if you...
- Vascular invasion or extrahepatic metastasis before ablation
- Presence of intractable ascites or hepatic encephalopathy
- Severe hepatic and renal dysfunction or other substantial organ disorders
- Active infections before or after ablation
- A history of other malignancies
- Failure to submit a completed questionnaire survey
- Lost to follow-up before reaching an outcome
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
Research Team
J
Jiang tianan, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here